French pharmaceutical company behind the scenes of Hanmi Pharm, the reason why Macron was angry-Chosun.com

French President Macron was firmly upset. The European Union has also turned around. This is due to an interview with Sanofi, CEO of the French multinational pharmaceutical company.

Paul Hudson, CEO of Sanofi, said in an interview with Bloomberg News on the 13th (local time) that “the United States was the first to support the Sanofi corona vaccine study (if a vaccine was developed) and will supply it first to the United States”. Bloomberg reported the day that CEO Paul Hudson was the leading article on the Internet website.

Hudson’s CEO is British. He said in an interview: “The United States government has the right to order the vaccine first because it has taken the risk and has boldly invested in it.”

Sanofi began developing corona vaccines last month with rival pharmaceutical company GlaxoSmithKline (GSK) in the United Kingdom. In addition, the United States Agency for Advanced Biomedical Research and Development (BARDA) invested $ 30 million (about 37 billion won). Sanofi is testing its flu vaccine against ingredients that enhance the immune response provided by the British pharmaceutical company GlaxoSmithKline. In the second half of this year, clinical trials for patients are planned.

France was deeply regretted by the Prime Minister and the Minister for the interview with CEO Hudson. The EU also commented on the fair use of the vaccine.

French Finance and Economy Minister Annes Panier Lunache said on 14: “It is unacceptable to first administer a vaccine to a specific country, for financial reasons.”

“The corona vaccine should be a public good for the world,” Edouard Philippe wrote on Twitter. “Equitable access to vaccines is not a compromise.”

Even the EU Commission said: “Corona vaccines should be in the international public interest and access opportunities should be fair and universal.”

When the situation worsened, French President Sanofi appeared on the air and said: “If Sanofi manages to develop a vaccine, everyone will benefit.” He added: “The goal is for vaccines to be supplied to the United States, France and Europe at the same time.”

On the 14th, Sanofi unilaterally broke the clinical contract for new imported diabetes drugs in 2015 from Hanmi Pharm, a Korean pharmaceutical company. Hanmi Pharm was in danger of losing 3.8 billion won worth of new drug exports.